Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.
Teva has urged the US Court of Appeals for the Federal Circuit to rehear its dispute with GlaxoSmithKline en banc, claiming that if the decision is upheld, “every skinny-labelled generic is at risk”.
Médecins Sans Frontières has warned that the European Commission’s commitment to the supplementary protection certificate system risks undermining its promise to improve drug accessibility.
The European Commission has fined Teva and its subsidiary Cephalon €60.5 million for agreeing to delay a cheaper generic version of sleep disorder drug modafinil.
The European Commission wants to increase access to generic medicines and crack down on anti-competitive behaviour in the pharmaceutical industry, a new plan has said.
The Delhi High Court has refused to grant AstraZeneca an injunction against the manufacture and sale of dapagliflozin by a group of India-based pharmaceutical companies.
US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.
The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.
The final version of guidelines issued by Canada’s federal drug price regulator last week has caused uproar among the pharma industry.
Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.